Viprynium is developed by Pfizer.

What development phase is Viprynium in?

Viprynium is FDA-approved (marketed).

What is the generic name of Viprynium?

PYRVINIUM is the generic (nonproprietary) name of Viprynium.

Last reviewed 2026-04-20 · How we verify

Viprynium (PYRVINIUM)

Pfizer · FDA-approved approved Small molecule Quality 5/100

At a glance

Generic name	PYRVINIUM
Sponsor	Pfizer
Drug class	pyrvinium
Target	Serine hydroxymethyltransferase, mitochondrial, Synaptojanin-1, Synaptojanin-2
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

REVerse Intestinal Metaplasia in the Stomach (REVISE) (PHASE2)
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer (PHASE1)
Use of Pyrvinium to Reverse Stomach Precancerous Conditions (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Viprynium CI brief — competitive landscape report
Viprynium updates RSS · CI watch RSS
Pfizer portfolio CI